ClinicalTrials.gg
CompletedNCT03876717SINBADUpdated Aug 23, 2022

Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea

A Phase 4 interventional study of Colesevelam Hydrochloride and Placebo oral capsule in Bile Acid Malabsorption and Chronic Diarrhea, sponsored by Lars Kristian Munck. Completed at 4 sites in Denmark. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-08-23.

Sponsored by Lars Kristian Munck · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Diarrhea with a site in Denmark — 1 open to participants now, 2 under way, none of them phase 3. Diarrhea · Denmark.

Enrollment
3rd of 11
255 · median 36
Started
2018
the only one that year
Phase 4
2 of 13
none open now
Registered
5th of 13
by date
Lead sponsor
1 of 13
Lars Kristian Munck

Among the 13 studies in Diarrhea with a site in Denmark, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2018, is one of 2 in phase 4, and was the 5th registered.

Diarrhea

880 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

Browse Diarrhea studies →

Open to participants now

1 of the 13 studies in Diarrhea with a site in Denmark is open now. Recruiting first, the newest first:

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diarrhea with a site in Denmark, or all of them as a file.
02

Study summary

Bile acid diarrhoea is a chronic disease that impairs quality of life. One in 100 has the condition and many suffer from the disease without knowing. The current test is called SeHCAT and is expensive and time-consuming and is unavailable in many places, including the US. The disease is often misdiagnosed as irritable bowel syndrome and estimated one third of patients with irritable bowel syndrome of the mixed type and the diarrhoea predominant type suffer from bile acid diarrhoea without knowing.

A blood test called 7α-hydroxy-4-cholestene-3-one (C4) could make it much easier to diagnose bile acid diarrhoea.

To establish the new test, the results of both C4 and SeHCAT are compared with the treatment effect of the drug called colesevelam.

We invite patients who are referred for the SeHCAT test to participate in the trial. The SeHCAT test takes two days that are one week apart. The study patients register stool habits with a diary in the week between the SeHCAT visits. Based on the diary results, we screen for eligibility; e.g. a certain degree/severity of diarrhoea is required for participation. We treat eligible study patients (i.e those with diarrhoea) with either colesevelam or placebo (medicine without effect) that is randomly assigned. 170 study patients need to complete the treatment.

We aim to validate (ie. compare) both the C4-test and the SeHCAT test with the colesevelam treatment response as the reference.

Read the detailed description

ISSUE Bile Acid Diarrhoea (BAD) affects 1% of the general population and many people live with the disease and the impaired quality of life it causes without knowing it. The current scintigraphic seleno-homo-taurocholic acid retention test (SeHCAT) is time-consuming, expensive and causes a diagnostic bottleneck. the SeHCAT test is unavailable in many countries including the US. The biomarker 7α-hydroxy-4-cholesten-3-one (C4) could provide a cheap and available diagnostic option to surmount the issue of the many undiagnosed patients. The pivotal step for this is validation of the C4-test with the placebo-controlled treatment effect.

PURPOSE

  1. To determine the efficacy and safety of colesevelam for treating Bile Acid Diarrhoea

    and

    1. To correlate both the current scintigraphic 75-Selenium conjugated Tauro-homocholic acid retention test (SeHCAT) and the biochemical marker of BAD 7alpha-hydroxy-4-cholesten-3-one (C4) with colesevelam treatment response, and to validate the cut-off values determined in the 'VABAD' trial

BACKGROUND Chronic diarrhoea affects 4-5% of the Western adult population and often results in specialist referral and endoscopies. Availability of the diagnostic SeHCAT test for BAD is limited, and BAD is often mistaken for the Irritable Bowel Syndrome (IBS). 32% of patients with two of the three IBS subtypes have BAD and the prevalence of BAD in the general population is thus approximately 1%.

DIAGNOSIS of Bile Acid Diarrhoea The current diagnostic test for BAD is the SeHCAT scintigraphic retention test using 75Selenium labelled Homo-tauro-cholic acid. The γ-emission is measured on day 1 and again on day 8. Seven-day SeHCAT retention rates of \<5% represent severe BAD, \<10% moderate BAD, and \<15% mild BAD. Although not properly validated, in observational studies 70-80% of patients with SeHCAT \<10% report a good response to cholestyramine. SeHCAT is unavailable in many countries including the the US, and clinicians instead rely on the patient's response to a therapeutic trial. However, the non-specific action and multiple side effects of the first line treatment with cholestyramine gives rise to multiple diagnostic pitfalls.

BIOMARKERS of Bile Acid Diarrhoea The recent increased insight into bile acid homeostasis and regulation has identified two biomarkers of BAD that may replace SeHCAT. 7α-hydroxy-4-cholestene-3-one (C4) is a bile acid precursor that correlates with bile acids synthesis rate. C4 is increased in BAD and has a sensitivity of 87% and specificity of 86% for diagnosing BAD defined by SeHCAT \<10%. However, analysis of C4 is technically difficult and is thus primarily used at centres with special interest and no access to SeHCAT.

Another biomarker Fibroblast Growth Factor 19 (FGF19) is released to the portal circulation from the terminal ileum in response to bile acid absorption. In the liver, FGF19 inhibits bile acid synthesis enticing a negative feedback loop. Fasting values of FGF19 correlate inversely with C4 and with SeHCAT, but the sensitivity of 67% and specificity of 77% for detecting even severe BAD is clinically insufficient.

Performance of the biomarkers in a modern Danish population The investigators studied C4 and FGF19 in two pilot studies in selected populations and further established a Danish national collaboration with four university hospitals and prospectively recruited 71 subjects. The positive test cut-off C4 ≥ 46 ng/mL had 52% sensitivity and 91% specificity for detecting BAD defined by SeHCAT ≤ 10%.

The analysis of these results and the literature suggest that taking account of liver cirrhosis, hyperbilirubinemia, and use of alcohol and statins may increase the diagnostic yield of C4.

TREATMENT OF BILE ACID DIARRHOEA Sequestrants bind bile acids in the intestinal lumen and thus alleviate the diarrhoea symptoms. The first line therapy is cholestyramine, but this powder-formulation is distasteful with a low patient acceptability. Colesevelam tablets are much better tolerated, and therefore placebo-controlled studies of colesevelam for BAD are warranted.

A systematic review found cholestyramine to be effective in 70% of BAD patients. A placebo-controlled trial of colesevelam in patients with suspected type 1 BAD. Diarrhoea intention-to-treat remission rates were 67% for colesevelam and 27% for placebo (p=0.057), but extreme selection criteria slowed recruitment and the study ended prematurely. Of note, only one of 19 dropped out due to side effects to colesevelam. In summary, colesevelam and cholestyramine have similar response rates of 70%. For a clinical trial, colesevelam is superior due to effective blinding and a much lower dropout rate.

METHODS Effect parameters in chronic diarrhoea Symptoms reported by diary The Bristol stool form scale (BSFS) classifies stool from 1 (hard lumps) to 7 (completely watery). Clinical trials often use a seven-day diary. Patients with an organic cause of diarrhoea more often have ≥3 stools per day or a consistently watery stool consistency (BSF≥6) than those who have a functional cause of the diarrhoea.

Criteria for activity and remission of diarrhoea (Hjortswang's criteria) Hjortswang correlated chronic diarrhoea symptoms with impact on quality of life for patients with microscopic colitis, and validated the definition of clinical activity as ≥ 3 stools per day or ≥ 1 watery stool (BSF 6-7) and remission as \<3 stools per day and \< 1 watery stool as a mean of the seven-day diary.

MEDICINE Colesevelam The hospital pharmacy of the Capital Region over-encapsulates colesevelam tablets with Capsugel® DBcaps®

Placebo Matrix placebo tablets, over-encapsulated as the colesevelam tablets. No side effects are expected.

Dose: One, two or three capsules of 625mg twice daily. The dose is titrated by a central blinded study nurse without contact to the investigators.

POWER CALCULATION Assumed

  • remission rate of 67% for colesevelam and 27% for placebo.
  • two-sided α = 0.05 and β = 0.20 (ie. 80% power).
  • 1:1 allocation. This gives 23 subjects with BAD in each arm (G.Power 3.1: z-test of two independent proportions). 27% of subjects in our prospective pilot study that would be eligible for the SINBAD study had SeHCAT \<10%. Thus, (2 x 23 / 27%) = 170 subjects.

BIOCHEMISTRY C4 and bile acid species are analysed with liquid chromatography - tandem mass spectrometry. FGF19 is analysed with ELISA (R\&D Systems, MN, USA).

The hospital laboratories of the participating centres perform the routine biochemical analyses.

STUDY PLAN Pre-screening

  1. We send a written invitation to eligible patients who already are referred for SeHCAT
  2. At the first SeHCAT visit, further information is provided and voluntary informed consent is obtained.

Study visit 1 - Day 1: start of baseline registration The investigator creates an electronic Case Record Form (EasyTrial) including medical and surgical history, medication, and physical status. Baseline blood analyses include ALT, ALP, bilirubin, amylase; and on indication HCG.

The investigator notifies the referring doctor.

The participants start Study Diary 1 (screening+baseline).

Study visit 2 - Day 8: Screening results - randomisation This is concurrent with the second SeHCAT visit. All subjects meet in the fasting for blood sampling. All subjects answer the baseline questionnaires (SHS, GSRS, SF36v2).

The screening diary is assessed:

Subjects without diarrhoea: cannot continue to randomisation.

  1. SeHCAT results are registered once available
  2. Result of the diagnostic work-up is registered at a six-month telephone follow-up.

Subjects with diarrhoea: continue to randomisation. The subject

  • is given a uniquely numbered treatment package
  • starts Study Diary 2
  • is telephoned by the central study nurse for the planning of dose titration

Telephone consultation - Day 9 (treatment day 2):

The study nurse takes a history of adverse events and titres the dose

Telephone consultation - day 13 (± 1 day): End of Run-in-period As on day 9.

Ad hoc telephone consultations Any change in dose mandates a follow-up telephone consult after 2-3 days.

Study visit 3 - Day 21 (+ 1-3 days) Intervention-End The intervention has ended on day 20.

The investigator:

  • Collects Study Diary 2
  • Takes a history of AEs
  • Collects surplus medication to assess compliance
  • Distributes questionnaires
  • Orders follow-up blood analysis
  • Schedules study-end telephone consultation

Telephone consultation - Study day 26 (± 2 day): Clinical Study end AE registration continues three days after the end of treatment.

The investigator:

  • Assess biochemical AEs

    o Informs of results

  • Takes a history of AEs
  • Takes action if needed

Six-month follow-up The questionnaires are redistributed. The patient's Medical file is checked and a telephone interview is done to note any conclusive diagnosis on the patients diarrhoea and (if any) anti-diarrhoea medication

03

Conditions studied

  • Bile Acid Malabsorption
  • Chronic Diarrhea

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient referred to Clinical Physiological/Nuclear Medicine departments for SeHCAT
  • Suspected Bile acid diarrhoea
  • Age > 18 years and under 80 years
  • women of fertile age must use safe during the treatment part of the study
  • Ability to give after written and oral information in Danish language

Exclusion criteria

Exclusion Criteria:

  • Inflammatory bowel disease, including microscopic colitis
  • Investigator assessed debilitating chronic disease e.g. World Health Organisation performance score 3-5
  • Prior treatment with colesevelam
  • Treatment with laxatives or anti-diarrhoeal drugs during the study

    • Except for stable dose the last four weeks of psyllium husk and opioids for pain
  • Breastfeeding women
  • Crucial medication that cannot be separated appropriately from colesevelam

    • i.e. taken one hour before or 4 hours after colesevelam
  • Oral anticoagulation, both warfarin, and new oral anticoagulation
  • Treatment with cyclosporine within two months
  • Bowel obstruction (subileus or ileus)
  • Biliary obstruction
  • Short bowel syndrome
  • Bowel ostomy
  • Allergy to colesevelam or its constituents
  • Allergy to placebo constituents (excluding lactose)
  • Investigator assessed high risk of non-compliance
  • If on statin/fibrate medication, unwilling to pause medication between study visits 1 and 2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Colesevelam, active arm

    Colesevelam hydrochloride, 625mg tablets. Overencapsulated with DB caps AAA for blinding. Oral use. Dose: 1, 2, or 3 capsules twice daily. Starting dose 2 capsules twice daily. Dose titration by specific criteria by a central study nurse Treatment duration 12 days

    Drug: Colesevelam Hydrochloride

  • Placebo comparator
    Placebo

    Inactive placebo tablets. Overencapsulated with DB caps AAA for blinding. Oral use. Dosage and treatment duration as specified for colesevelam

    Drug: Placebo oral capsule

Interventions

  • DrugColesevelamStudies of ColesevelamColesevelam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.

    Also known as: Cholestagel

  • DrugPlacebo oral capsule

    Inactive placebo tablets over-encapsulated with DB caps AAA

    Also known as: Inactive placebo

06

What researchers measure

Primary outcomes

  1. Intention-to-treat diarrhoea remission rate defined by the Hjortswang criteria for colesevelam in patients with BAD defined by C4 > 46 ng/mL

    drop-outs are set as treatment failures in the ITT analysis if less than five of the last seven treatment days that comprise the endpoint assessment period are complete. If five or more of these days are complete, a mean of these days will be used for calculating the Hjortswang response criterium. We will fit an appropriate generalized linear mixed-effects model with an unstructured covariance pattern of the chance of response with colesevelam versus placebo. In addition, baseline adjustments for the severity of diarrhoea (mean per day sum of Bristol type 6 and 7 stools) and the severity of bile acid malabsorption (visit 2 C4 value) will be made

    Time frame: Intervention days 6 through 12 (last seven intervention days)

Secondary outcomes

  1. Per protocol diarrhoea remission rate defined by the Hjortswang criteria for colesevelam in patients with BAD defined by C4 > 46 ng/mL

    this is an efficacy (de jure) estimand for colesevelam. Modelling as for the primary endpoint but with imputation of missing data as if all patients had adhered. This includes all patients with bile acid diarrhoea and complies with a per protocol principle.

    Time frame: Intervention days 6 through 12 (last seven intervention days)

  2. Intention-to-treat diarrhoea remission rate defined by the Hjortswang criteria for colesevelam in patients with BAD defined by SeHCAT <= 10%

    Statistical analysis: as the primary endpoint but with baseline adjustment for SeHCAT, not C4. Sensitivity analyses: as for the primary endpoint. Instead of differing C4 cutoffs, the SeHCAT cutoffs ≤ 5%, and ≤ 15% will be assessed

    Time frame: Intervention days 6 through 12 (last seven intervention days)

  3. Per protocol diarrhoea remission rate defined by the Hjortswang criteria for colesevelam in patients with BAD defined by SeHCAT <= 10%

    Statistical analysis: this is an efficacy (de jure) estimand for colesevelam. Modelling as for the primary endpoint with baseline adjustment for SeHCAT and with imputation of missing data as if all patients had adhered.

    Time frame: Intervention days 6 through 12 (last seven intervention days)

  4. placebo-controlled effect of colesevelam in patients with bile acid diarrhoea defined by C4 >46 ng/mL on the absolute number of stools as mean per day over 6 or 7 days

    Statistical analysis: as for the primary endpoint but instead of the binary Hjortswang response criteria as outcome, continuous variables will be modelled with suiting baseline adjustment

    Time frame: Baseline period compared with Intervention days 6 through 12 (last seven intervention days)

  5. placebo-controlled effect of colesevelam in patients with bile acid diarrhoea defined by C4 >46 ng/mL on the total number of Bristol type 6 and 7 stools as a mean over 6 or 7 days

    Statistical analysis: as for the primary endpoint but instead of the binary Hjortswang response criteria as outcome, continuous variables will be modelled with suiting baseline adjustment

    Time frame: Baseline period compared with Intervention days 6 through 12 (last seven intervention days)

  6. The de facto effectiveness of colesevelam on health related quality of life assessed as the sum of Short Health Scale scores

    Statistical analysis: modelling with adjustment for baseline SHS score

    Time frame: Baseline period compared with Intervention days 6 through 12 (last seven intervention days)

07

Study locations

4 sites
  • Aalborg University Hospital
    Aalborg, 9000, Denmark
  • Aarhus University Hospital
    Aarhus, 8200, Denmark
  • Hvidovre University Hospital
    Hvidovre, 2650, Denmark
  • Zealand University Hospital
    Køge, 4600, Denmark
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — An electronic Data Management Plan has been created on dmponline.dcc.ac.uk with details on management of raw data, refined data, metadata, organising, storing, backup, sharing, and curation of the data The biological material is saved anonymously and destroyed 15 years after study end. Positive and negative results will be published in an international peer-reviewed journal. We regard the study protocol, consent form, questionnaires, statistical analysis plan, raw data, refined data, statistical code, and metadata as long-term valuable data to be shared after de-identification in the repository of the Danish National Archives to be available after the primary article is published. Data access is unrestricted and indefinite and with investigator assistance for the first 36 months.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: De-identified data will be made available without restrictions after articles from the study have been published

Access criteria: Data access is unrestricted and indefinite and with investigator assistance for the first 36 months. Publications need proper citing.

Data sharing details ↗ · dmponline.dcc.ac.uk

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Jul 2021, 32 months.

Of 32 non-industry phase 4 interventional studies under Diarrhea, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's 32 months is below that.

Counting every sponsor, half of 37 studies reached it within 32 months; a quarter within 14 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2019
First posted
Mar 15, 2019
StartActual
Oct 25, 2018
Primary completionActual
Jul 1, 2021
CompletionActual
Feb 13, 2022
Last update
Aug 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03876717
Lead sponsor
Lars Kristian Munck
Collaborators
Pierre and Marie Curie University
Responsible party
Lars Kristian Munck (Senior Physician, Clinical Associate Professor, Sponsor-Investigator, Zealand University Hospital) — Sponsor-investigator
First posted
Mar 15, 2019
Start date
Oct 25, 2018
Primary completion
Jul 1, 2021
Completion
Feb 13, 2022
Last update
Aug 23, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colesevelam

Start the discussion